AI Article Synopsis
- - The introduction of PARP inhibitors (PARPi) has significantly impacted ovarian cancer treatment, but in 2022, key drugs like Rucaparib, Olaparib, and Niraparib lost approval for later-stage therapies due to safety concerns.
- - The need for new treatment options is urgent, leading to the investigation of combining PARPi with immune checkpoint inhibitors (ICIs) as a promising strategy for ovarian cancer.
- - This article reviews how PARPi and ICIs work together, the supporting evidence for their combined effectiveness, and important factors to consider for their future development in treating ovarian cancer.
Article Abstract
The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has brought about significant changes in the field of ovarian cancer treatment. However, in 2022, Rucaparib, Olaparib, and Niraparib, had their marketing approval revoked for third-line and subsequent therapies due to an increased potential for adverse events. Consequently, the exploration of new treatment modalities remains imperative. Recently, the integration of PARPi with immune checkpoint inhibitors (ICIs) has emerged as a potential remedy option within the context of ovarian cancer. This article offers a comprehensive examination of the mechanisms and applications of PARPi and ICIs in the treatment of ovarian cancer. It synthesizes the existing evidence supporting their combined use and discusses key considerations that merit attention in ongoing development efforts.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11337781 | PMC |
| http://dx.doi.org/10.1186/s12967-024-05583-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!